What is a key safety rule for using LABAs in asthma treatment?

The correct approach when using Long-Acting Beta Agonists (LABAs) in asthma treatment is that they must always be combined with an inhaled corticosteroid (ICS). This combination is essential because LABAs are designed to provide long-term bronchodilation and control asthma symptoms, but on their own, they do not address the underlying inflammation associated with asthma. Inhaled corticosteroids are crucial in managing this inflammation, thus enhancing overall control of asthma and reducing the risk of exacerbations.

Using LABAs alone can lead to a significant safety concern, as there is an increased risk of asthma-related complications, including severe exacerbations. The combination therapy allows for improved asthma management, leading to better control of symptoms and a decrease in the frequency of asthma attacks. Therefore, adhering to the guideline of always using a LABA in conjunction with an inhaled corticosteroid is a key safety rule.